Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics
Liquidia Technologies, Inc. (LQDA)
Today's Latest Price: $5.75 USD
0.24 (-4.01%)
Updated Jan 28 12:07pm
Add LQDA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
LQDA Stock Summary
- LQDA's went public 1.51 years ago, making it older than merely 1.99% of listed US stocks we're tracking.
- As for revenue growth, note that LQDA's revenue has grown 219.19% over the past 12 months; that beats the revenue growth of 97.06% of US companies in our set.
- In terms of volatility of its share price, LQDA is more volatile than 92.72% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Liquidia Technologies Inc are AGEN, MRSN, WVE, CARA, and FATE.
- LQDA's SEC filings can be seen here. And to visit Liquidia Technologies Inc's official web site, go to www.liquidia.com.
LQDA Daily Price Range
LQDA 52-Week Price Range
LQDA Stock Price Chart More Charts
LQDA Price/Volume Stats
| Current price | $5.75 | 52-week high | $20.05 |
| Prev. close | $5.99 | 52-week low | $2.65 |
| Day low | $5.67 | Volume | 55,618 |
| Day high | $6.11 | Avg. volume | 166,144 |
| 50-day MA | $4.42 | Dividend yield | N/A |
| 200-day MA | $6.15 | Market Cap | 107.28M |
Liquidia Technologies, Inc. (LQDA) Company Bio
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.
Top Stories View All
3 Things Investors Need to Know About the Wuhan Virus Outbreak
Best & Worst Performing Stock Industries for January 27, 2020
Best & Worst Performing Small Cap Stocks for January 27, 2020
Best & Worst Performing Mid Cap Stocks for January 27, 2020
Best & Worst Performing Large Cap Stocks for January 27, 2020
View All Top Stories
Loading social stream, please wait...